View Older Stories View More Recent Stories

Nov 29, 2023 08:46AM AbbVie (ABBV) Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin for Patients with Previously Treated NSCLC
Nov 29, 2023 08:45AM AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Nov 27, 2023 07:01AM AbbVie (ABBV) Reports FDA and EMA Updates for Epcoritamab
Nov 27, 2023 07:00AM AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
Nov 20, 2023 08:45AM Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever
Nov 16, 2023 07:02AM AbbVie (ABBV) Reports Publication Showing UBRELVY Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
Nov 16, 2023 07:00AM Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
Nov 8, 2023 08:45AM Natrelle® Unveils New "For Every BODY" Campaign
Nov 1, 2023 08:45AM BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before
Oct 27, 2023 07:38AM AbbVie Reports Third-Quarter 2023 Financial Results
Oct 24, 2023 08:31AM Allergan (ABBV) Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Oct 24, 2023 08:30AM Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Oct 19, 2023 08:45AM Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project
Oct 15, 2023 11:15AM AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
Oct 12, 2023 05:30AM AbbVie (ABBV) Reports Upadacitinib Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo
Oct 12, 2023 05:25AM AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
Oct 11, 2023 08:30AM AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Oct 10, 2023 08:45AM AbbVie (ABBV) Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis
Oct 10, 2023 08:45AM AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
Oct 5, 2023 08:05AM AbbVie (ABBV) Exercises Exclusive Right to Acquire Mitokinin
Oct 5, 2023 08:05AM AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
Oct 4, 2023 11:11AM AbbVie (ABBV) Announces Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484
Oct 4, 2023 11:07AM Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
Oct 4, 2023 08:00AM AbbVie to Host Third-Quarter 2023 Earnings Conference Call
Oct 3, 2023 07:00AM Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field
Sep 29, 2023 07:15AM AbbVie (ABBV) Reports Results from Phase 3 CANOVA Study of Venetoclax
Sep 29, 2023 07:15AM AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
Sep 25, 2023 07:45AM AbbVie (ABBV) Announces European Commission Approval of TEPKINLY for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sep 25, 2023 07:45AM AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sep 18, 2023 09:01AM AbbVie (ABBV) Reports Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA
Sep 18, 2023 09:00AM Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence
Sep 13, 2023 11:00AM AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"
Sep 12, 2023 08:32AM AbbVie's (ABBV) SKYRIZI Met All Primary and Secondary Endpoints Versus Stelara in Head-to-Head Study in Crohn's Disease
Sep 12, 2023 08:30AM AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease
Sep 8, 2023 11:23AM AbbVie Declares Quarterly Dividend
Sep 6, 2023 08:45AM Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs
Sep 6, 2023 08:00AM AbbVie to Present at the Morgan Stanley Healthcare Conference
Aug 30, 2023 09:00AM Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)
Aug 28, 2023 08:45AM AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Risankizumab in Ulcerative Colitis
Aug 28, 2023 08:45AM AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis
Aug 17, 2023 05:32AM AbbVie (ABBV) Announces EU Approval of AQUIPTA for Migraine in Adults
Aug 17, 2023 02:00AM AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
Aug 1, 2023 08:45AM Allergan Aesthetics Announces First Ever JUVÉDERM® Day
Jul 27, 2023 07:38AM AbbVie Reports Second-Quarter 2023 Financial Results
Jul 26, 2023 09:04AM AbbVie (ABBV) and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
Jul 26, 2023 09:00AM AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
Jul 26, 2023 08:05AM AbbVie (ABBV) Reports SKYRIZI Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis
Jul 26, 2023 08:05AM SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
Jul 25, 2023 07:04AM AbbVie (ABBV) Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib in Hidradenitis Suppurativa
Jul 24, 2023 08:05AM AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
View More Recent Stories View Older Stories